About InDex Pharmaceuticals
InDex Pharmaceuticals is a company based in Stockholm (Sweden) founded in 2000. InDex Pharmaceuticals has raised $45.42 million across 6 funding rounds from investors including SEB, Vinnova and NeoMed. InDex Pharmaceuticals offers products and services including Investment Services and Insights Platform. InDex Pharmaceuticals operates in a competitive market with competitors including BeiGene, Moderna, Incyte, ALX Oncology and MorphoSys, among others.
- Headquarter Stockholm, Sweden
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Flerie Ab
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$45.42 M (USD)
in 6 rounds
-
Latest Funding Round
$14.12 M (USD), Private Equity Round
Sep 01, 2019
-
Investors
SEB
& 4 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of InDex Pharmaceuticals
InDex Pharmaceuticals offers a comprehensive portfolio of products and services, including Investment Services and Insights Platform.
Provides funding and support for biotech startups
Offers updates on pharmaceutical advancements and portfolio news
People of InDex Pharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of InDex Pharmaceuticals
InDex Pharmaceuticals has successfully raised a total of $45.42M across 6 strategic funding rounds. The most recent funding activity was a Private Equity Round of $14.12 million completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Private Equity Round — $14.1M
-
First Round
First Round
(20 Jan 2011)
- Investors Count 5
Investors in InDex Pharmaceuticals
InDex Pharmaceuticals has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include SEB, Vinnova and NeoMed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital funding is provided to Swedish companies across sectors.
|
Founded Year | Domain | Location | |
|
Stage-agnostic life sciences-focused VC firm investing in North America & Europe
|
Founded Year | Domain | Location | |
|
Investments in deep-tech, life sciences, and transformative tech are managed.
|
Founded Year | Domain | Location |
Investments & Acquisitions by InDex Pharmaceuticals
Financial Statements - InDex Pharmaceuticals
Index Pharmaceuticals Comparisons
Competitors of InDex Pharmaceuticals
InDex Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Moderna, Incyte, ALX Oncology and MorphoSys, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
ALX Oncology is focused on advancing cancer treatment therapies.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
Latest news on Index Pharmaceuticals
Frequently Asked Questions about InDex Pharmaceuticals
InDex Pharmaceuticals was founded in 2000 and raised its 1st funding round 11 years after it was founded.
InDex Pharmaceuticals is headquartered in Stockholm, Sweden.
InDex Pharmaceuticals is a funded company, having raised a total of $45.42M across 6 funding rounds to date. The company's 1st funding round was a Grant of $200.56K, raised on Jan 20, 2011.
InDex Pharmaceuticals was established in 2000 in Stockholm, Sweden, within the pharmaceuticals sector focused on inflammatory bowel disease. Treatments for ulcerative colitis are developed, including Kappaproct, a DNA-based immunomodulatory sequence medication that delivers targeted anti-inflammatory effects to heal mucosal tissue and alleviate symptoms in severe cases. A diagnostic tool, DiBiCol, is also provided to distinguish ulcerative colitis from Crohns disease among major inflammatory bowel conditions.
InDex Pharmaceuticals's top competitors include Moderna, BeiGene and Strand Therapeutics.
InDex Pharmaceuticals offers Investment Services and Insights Platform.
InDex Pharmaceuticals has 5 investors. Key investors include SEB, Vinnova, NeoMed, Industrifonden, and EIC Fund.